Premium
Surface Plasmon Resonance Analysis of Binding Kinetics and Affinity of Serum Protective Antigen Antibodies in Non‐Human Primates Following Vaccination and Anthrax Aerosol Challenge
Author(s) -
Jones Kelly Jean,
Gainey Melicia,
Sivko Gloria,
Battelle Dan Read
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.2_supplement.245
Subject(s) - bacillus anthracis , vaccination , surface plasmon resonance , anthrax vaccines , antibody , antigen , immune system , kinetics , receptor–ligand kinetics , chemistry , recombinant dna , anthrax toxin , immunology , virology , medicine , fusion protein , biology , biochemistry , immunization , materials science , nanotechnology , receptor , nanoparticle , genetics , quantum mechanics , physics , gene , bacteria , dna vaccination
The immune response to anthrax protective antigen (PA) in the non‐human primate (NHP) was characterized by anti‐PA IgG ELISA, toxin neutralization assay (TNA), and antibody binding kinetics and affinity after vaccination and challenge. NHPs were vaccinated twice with AVA or recombinant PA (rPA) vaccine administered four weeks apart and aerosol challenged with Bacillus anthracis Ames spores 10 weeks post initial vaccination. Serum samples were collected every two weeks throughout the vaccination and challenge time periods. Serum immunoglobulins were analyzed for anti‐PA binding kinetics and affinity on a Biacore 3000 at five concentrations against rPA covalently attached to a CM4 chip. The general trend for both vaccine groups was a decrease in both k d and k a immediately after vaccination and challenge. The net effect of both vaccination and aerosol challenge on binding affinity for PA was a decrease in K D (higher affinity). The average K D values for the AVA and rPA vaccinated NHPs post aerosol challenge (day 100) were 2.5 nM and 3.0 nM respectively. Data will be presented that demonstrate the effect of multiple exposures to PA (via vaccine and/or challenge) on anti‐PA antibody maturation. This work was supported by NIAID Contract No. N01‐AI‐30061.